Recent Insider Transactions • Jul 01
Independent Non-Executive Director recently sold AU$126k worth of stock On the 26th of June, John Diddams sold around 200k shares on-market at roughly AU$0.63 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Reported Earnings • May 27
Full year 2026 earnings released: EPS: NZ$0.014 (vs NZ$0.011 loss in FY 2025) Full year 2026 results: EPS: NZ$0.014 (up from NZ$0.011 loss in FY 2025). Revenue: NZ$103.9m (up 23% from FY 2025). Net income: NZ$4.68m (up NZ$8.49m from FY 2025). Profit margin: 4.5% (up from net loss in FY 2025). The move to profitability was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Biotechs industry in Australia. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Breakeven Date Change • May 20
Forecast breakeven date pushed back to 2027 The 3 analysts covering Aroa Biosurgery previously expected the company to break even in 2026. New consensus forecast suggests the company will make a profit of NZ$7.96m in 2027. Average annual earnings growth of 87% is required to achieve expected profit on schedule. Breakeven Date Change • May 01
Forecast breakeven date pushed back to 2027 The 3 analysts covering Aroa Biosurgery previously expected the company to break even in 2026. New consensus forecast suggests the company will make a profit of NZ$11.5m in 2027. Average annual earnings growth of 99% is required to achieve expected profit on schedule. Ankündigung • Mar 30
Aroa Biosurgery Limited Completes Randomised Controlled Trial for Symphony Aroa Biosurgery Limited announced completion of its randomised controlled trial (RCT) evaluating Symphony, with a preliminary study read-out indicating the trial achieved its primary endpoint. Symphony is AROA's Cellular, Acellular and Matrix-like Product (CAMP), or skin substitute, designed for the treatment of hard-to-heal wounds, including diabetic foot ulcers (DFUs) and venous leg ulcers. The product combines multiple layers of AROA ECM with high molecular weight hyaluronic acid. The prospective, multi-centre, randomised trial evaluated the safety and performance of Symphony in the treatment of chronic Wagner grade 1 and 2 non-healing diabetic foot ulcers. Patients were randomised to receive either Symphony or standard of care (SOC) dressings on a weekly basis until wound healing or for up to 12 weeks. The study design provided for recruitment of up to 150 patients across multiple sites in the United States. The primary endpoint assessed whether more diabetic foot ulcers healed within the 12-week treatment period with Symphony compared with SOC. Based on the preliminary read-out, the Company believes the trial met its primary endpoint. AROA expects that, once confirmed through final analysis and publication, the results will further support Symphony's clinical efficacy in the management of diabetic foot ulcers. The Company also believes publication of the full study results will help meet the high standard of clinical evidence likely to be required under future reimbursement policies. Ankündigung • Feb 17
Aroa Biosurgery Limited to Report Fiscal Year 2026 Results on May 31, 2026 Aroa Biosurgery Limited announced that they will report fiscal year 2026 results at 10:00 AM, AUS Eastern Standard Time on May 31, 2026 Ankündigung • Oct 09
Aroa Biosurgery Limited to Report Q2, 2026 Results on Oct 16, 2025 Aroa Biosurgery Limited announced that they will report Q2, 2026 results Pre-Market on Oct 16, 2025 Ankündigung • Aug 28
Aroa Biosurgery Announces the Findings of the First in Human Study Inviding Its New ENIVO Platform Technology AROA announced the findings of the first in human study involving its new ENIVO platform technology. The study is the subject of a peer-reviewed publication entitled Prospective, First-in-Human Clinical Evaluation of a Novel Tissue Apposition Device (ENIVO™?) Following Simple Unilateral Mastectomy, which was published in the well-respected journal, Plastic and Reconstructive Surgery, Global Open. The ENIVO platform is designed for the management of 'dead space,' which is an open cavity created by surgical separation or excision of soft tissue. Dead spaces commonly fill with seroma, which can lead to secondary complications, increase the risk of infection, and lengthen hospital stays for patients. AROA's novel ENIVO system is comprised of a wearable vacuum pump connected to a tube and an Aroa ECM sleeve which is implanted within the patient's body. It delivers suction to the surgical site and allows the tissue surfaces at the surgical site to be held closely together, aiming to eliminate the dead space, remove fluid, and improve the speed and quality of healing. The multi-center study, which involved ten patients who had undergone simple unilateral mastectomy where all tissue from one breast is removed, was conducted in New Zealand and led by Associate Professor Michelle B. Locke, MBChB MD. The ENIVO system was used as an alternative to a surgical drain, which is the current standard of care. The shortcomings of drains are well-known - they can fail due to blockages and often lead to seroma formation. Seromas (a collection of fluid that accumulates in a surgical cavity) are one of the most common complications following mastectomy, with reported incidence rates as high as 22-43%. Seromas are associated with delayed wound healing, increased risk of infection and unsatisfactory aesthetic results. The study monitored the patients for a period of three months postoperatively and found that the ENIVO device performed as designed and all patients healed well, with only one clinically relevant seroma recorded. AROA estimates the market opportunity for ENIVO to be in excess of USD 1B, and is actively pursuing commercialisation, with two out of three of the components already having received US FDA clearance. ENIVO is a device in development and is not currently cleared for use in the tested configuration within the United States. Ankündigung • Jul 22
Aroa Biosurgery Limited to Report Q1, 2026 Results on Jul 29, 2025 Aroa Biosurgery Limited announced that they will report Q1, 2026 results at 9:00 AM, E. Australia Standard Time on Jul 29, 2025 Ankündigung • Jun 27
Aroa Biosurgery Limited to Report First Half, 2026 Results on Nov 25, 2025 Aroa Biosurgery Limited announced that they will report first half, 2026 results on Nov 25, 2025 Ankündigung • Jun 25
Aroa Biosurgery Limited, Annual General Meeting, Aug 20, 2025 Aroa Biosurgery Limited, Annual General Meeting, Aug 20, 2025. Ankündigung • May 02
Aroa Biosurgery Hits Evidence Milestone with Real-World Study Validating the Efficacy of Endoform in Treating Venous Leg Ulcers Aroa Biosurgery announced a milestone in clinical evidence. There are now over 100 peer-reviewed studies describing the efficacy of the company's proprietary AROA ECM technology. AROA's most recent publication was a large retrospective analysis of real-world evidence (RWE) from wound care centers in the US, assessing the efficacy of the company's Endoform NaturalTM product in treating venous leg ulcers (VLUs), in comparison to a leading reconstituted collagen dressing. VLUs are open sores that are hard-to-heal because of impaired blood flow and can be very debilitating and painful. These types of wounds are difficult for clinicians to treat successfully. For example, only 40% of VLUs can be healed after 3 months of treatment and there is a relatively high chance that these wounds will recur. The peer-reviewed study, entitled "Clinical Efficacy of Ovine Forestomach Matrix and Collagen/Oxidized Regenerated Cellulose for the Treatment of Venous Leg Ulcers: A Retrospective Comparative Real-World Evidence Study" was published in the open access journal 'International Wound Journal in April 2025. The study compared 470 VLUs that had been treated with Endoform Natural to 360 VLUs that had been treatment with a reconstituted collagen product. The study used existing data from 223 wound care centers with minimal inclusion or exclusion criteria so that ' real-world' use of both products could be compared. The study found that VLUs treated with Endoform Natural healed up to 8 weeks faster versus the comparator group, and the chances of the wound healing were significantly improved when Endoform Natural was used as part of treatment. The striking difference in the healing outcomes demonstrate the potential for considerable cost reductions and improvements in patient quality of life, due to the significant improvements seen when VLUs were treated using Endoform Natural. This is the second large retrospective RWE comparing Endoform Natural to a leading reconstituting collagen dressing. A previous study included the analysis of over 2,200 diabetic foot ulcers (DFUs) and also demonstrated significantly faster healing of DFUs using Endoform Natural. Kolluri R, Lugli M, Villalba L, Varcoe R, Maleti O, Gallardo F, et al. An estimate of the economic burden of venous leg ulcers associated with deep venous disease. Vasc Med. 2022;27(1):63-72. Bosque BA, Frampton C, Chaffin AE, Bohn GA, Woo K, DeLeonardis C, Lepow BD, Melin MM, Madu T, Dowling SG, May BCH. Retrospective real-world comprehensive effectiveness of ovine forestomach matrix and collagen/ORC in the treatment of diabetic foot ulcers. Int Wound J. 2022;19:7):741-753. Ankündigung • Apr 22
Aroa Biosurgery Limited to Report Q4, 2025 Results on Apr 29, 2025 Aroa Biosurgery Limited announced that they will report Q4, 2025 results Pre-Market on Apr 29, 2025 Ankündigung • Jan 22
Aroa Biosurgery Limited to Report Q3, 2025 Results on Jan 29, 2025 Aroa Biosurgery Limited announced that they will report Q3, 2025 results Pre-Market on Jan 29, 2025 Ankündigung • Oct 15
Aroa Biosurgery Limited to Report Q2, 2025 Results on Oct 22, 2024 Aroa Biosurgery Limited announced that they will report Q2, 2025 results Pre-Market on Oct 22, 2024 Recent Insider Transactions • Oct 06
Independent Non-Executive Director recently bought AU$150k worth of stock On the 30th of September, Catherine Mohr bought around 436k shares on-market at roughly AU$0.34 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$326k more in shares than they have sold in the last 12 months. Breakeven Date Change • Sep 05
Forecast to breakeven in 2026 The 5 analysts covering Aroa Biosurgery expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of NZ$7.36m in 2026. Average annual earnings growth of 56% is required to achieve expected profit on schedule. Breakeven Date Change • Aug 12
Forecast to breakeven in 2026 The 5 analysts covering Aroa Biosurgery expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of NZ$8.87m in 2026. Average annual earnings growth of 101% is required to achieve expected profit on schedule. Breakeven Date Change • Jul 23
Forecast to breakeven in 2026 The 5 analysts covering Aroa Biosurgery expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of NZ$9.26m in 2026. Average annual earnings growth of 99% is required to achieve expected profit on schedule. Ankündigung • May 26
Aroa Biosurgery Limited, Annual General Meeting, Jul 23, 2024 Aroa Biosurgery Limited, Annual General Meeting, Jul 23, 2024. Reported Earnings • May 21
Full year 2024 earnings released: NZ$0.031 loss per share (vs NZ$0.001 loss in FY 2023) Full year 2024 results: NZ$0.031 loss per share (further deteriorated from NZ$0.001 loss in FY 2023). Revenue: NZ$69.1m (up 9.0% from FY 2023). Net loss: NZ$10.6m (loss widened NZ$10.2m from FY 2023). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Biotechs industry in Australia. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Breakeven Date Change • May 21
Forecast breakeven date pushed back to 2026 The 5 analysts covering Aroa Biosurgery previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 34% to 2025. The company is expected to make a profit of NZ$10.3m in 2026. Average annual earnings growth of 99% is required to achieve expected profit on schedule. Ankündigung • May 15
Aroa Biosurgery Limited to Report Fiscal Year 2024 Results on May 21, 2024 Aroa Biosurgery Limited announced that they will report fiscal year 2024 results Pre-Market on May 21, 2024 Recent Insider Transactions • Feb 24
Non-Executive Director recently bought AU$176k worth of stock On the 16th of February, Philip McCaw bought around 326k shares on-market at roughly AU$0.54 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Breakeven Date Change • Feb 02
Forecast to breakeven in 2025 The 5 analysts covering Aroa Biosurgery expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of NZ$2.26m in 2025. Average annual earnings growth of 114% is required to achieve expected profit on schedule. Reported Earnings • Nov 30
First half 2024 earnings released: NZ$0.018 loss per share (vs NZ$0.005 profit in 1H 2023) First half 2024 results: NZ$0.018 loss per share (down from NZ$0.005 profit in 1H 2023). Revenue: NZ$31.9m (up 8.6% from 1H 2023). Net loss: NZ$6.31m (down 497% from profit in 1H 2023). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Biotechs industry in Australia. Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Breakeven Date Change • Nov 29 The 4 analysts covering Aroa Biosurgery previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of NZ$7.60m in 2025. Average annual earnings growth of 2.3% is required to achieve expected profit on schedule.
Ankündigung • Jun 30
Aroa Biosurgery Limited to Report First Half, 2024 Results on Nov 28, 2023 Aroa Biosurgery Limited announced that they will report first half, 2024 results on Nov 28, 2023 Ankündigung • Jun 07
Aroa Biosurgery Limited, Annual General Meeting, Aug 03, 2023 Aroa Biosurgery Limited, Annual General Meeting, Aug 03, 2023. Agenda: To consider the election of directors. Breakeven Date Change • Jun 01
Forecast breakeven date pushed back to 2025 The 5 analysts covering Aroa Biosurgery previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of NZ$8.04m in 2025. Average annual earnings growth of 83% is required to achieve expected profit on schedule. Reported Earnings • May 31
Full year 2023 earnings released: NZ$0.001 loss per share (vs NZ$0.025 loss in FY 2022) Full year 2023 results: NZ$0.001 loss per share (improved from NZ$0.025 loss in FY 2022). Revenue: NZ$63.4m (up 60% from FY 2022). Net loss: NZ$396.0k (loss narrowed 95% from FY 2022). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Australia. Ankündigung • May 25
Aroa Biosurgery Limited to Report Fiscal Year 2023 Results on May 31, 2023 Aroa Biosurgery Limited announced that they will report fiscal year 2023 results Pre-Market on May 31, 2023 Breakeven Date Change • May 01
Forecast breakeven date moved forward to 2024 The 5 analysts covering Aroa Biosurgery previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 91% to 2023. The company is expected to make a profit of NZ$18.8k in 2024. Average annual earnings growth of 88% is required to achieve expected profit on schedule. Breakeven Date Change • Apr 20
Forecast breakeven date pushed back to 2025 The 5 analysts covering Aroa Biosurgery previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 82% per year to 2024. The company is expected to make a profit of NZ$8.68m in 2025. Average annual earnings growth of 89% is required to achieve expected profit on schedule. Breakeven Date Change • Feb 12
Forecast breakeven date moved forward to 2024 The 5 analysts covering Aroa Biosurgery previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 88% to 2023. The company is expected to make a profit of NZ$456.3k in 2024. Average annual earnings growth of 89% is required to achieve expected profit on schedule. Breakeven Date Change • Feb 10
Forecast breakeven date moved forward to 2024 The 6 analysts covering Aroa Biosurgery previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 80% to 2023. The company is expected to make a profit of NZ$1.02m in 2024. Average annual earnings growth of 150% is required to achieve expected profit on schedule. Board Change • Jan 05
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Non-Executive Director Catherine Mohr was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Dec 17
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Non-Executive Director Catherine Mohr was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. 
